
News|Videos|June 17, 2025
RX Review: Collaborating to strengthen RSV prevention efforts
Fact checked by: Morgan Ebert, Executive Editor, Victoria Johnson
In this video, the last in a 3-part series, panelists discuss future directions in the field and the importance of multispecialty collaboration.
Advertisement
Advertisement
As RSV prevention tools expanded, clinicians faced new decisions around allocation, coordination, and outreach. In the final installment of this 3-part HCP Live Network RX Review roundtable, moderator Albert Rizzo, MD, chief medical officer of the American Lung Association, concluded the discussion with Tina Tan, MD, and Joanne Nazif, MD. The panel focused on how prevention strategies had evolved and emphasized the growing need for collaboration across pediatrics, pulmonology, and infectious disease.
Related to this article

A Contemporary Pediatrics Peer Exchange panel reviews RSV risk, testing, maternal vaccination, and long-acting monoclonal antibodies, and where infants still slip through the cracks.

Completing the DTaP primary series was 96.2% effective against pertussis in Alaska children aged 6 months to 6 years during a record 2024 outbreak.

CDC confirmed the first pediatric flu death of 2026-27, linked to H1N1, as early flu activity rises in 2026.

With California WNV activity at a 5-year high, CHLA outlines age-based repellent and bite-prevention guidance for children.

Missed the AAP's new congenital measles guidance? This easy-to-read FAQ covers what pediatric clinicians need to know.

Johanna Chang, MD, offers guidance on vaccination, infection prophylaxis, and clinical warning signs in children receiving biologic therapies.

A GBD analysis of 204 countries estimated measles cases in children under 5 rose from 11.1 million in 2019 to 15.6 million in 2023.
Advertisement
Advertisement

